MedTrace Logo

Stomach Cancer Exosome-based Detection

NCT06342427 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 809

Last updated 2024-07-08

No results posted yet for this study

Summary

Gastric cancer continues to have a poor prognosis primarily due to the inability to detect it in its early stages. This study will develop and validate a blood assay to facilitate the non-invasive detection of gastric cancer.

Conditions

  • Gastric Cancer
  • Gastric Adenocarcinoma
  • Gastric Cancer Stage
  • Gastric Neoplasm
  • Gastric Lesion
  • Gastric Cancer in Situ
  • Gastric Cancer Stage IV
  • Gastric Cancer Stage IIIB
  • Gastric Cancer Stage III
  • Gastric Cancer Stage IB
  • Gastric Cancer Stage IA
  • Gastric Cancer, Stage 0
  • Gastric Cancer Stage IIIA
  • Gastric Cancer Stage II
  • Gastric Cancer TNM Staging
  • Gastric Cancer Metastatic to Lung
  • Gastric Cancer Metastatic to Liver
  • Gastric Cancer Stage I
  • Gastric Cancer TNM Staging Primary Tumor (T) T2B

Interventions

DIAGNOSTIC_TEST

DESTINEX

A panel of microRNA, whose expression level is tested in serum samples.

Sponsors & Collaborators

  • City of Hope Medical Center

    lead OTHER

Principal Investigators

  • Ajay Goel, PhD · City of Hope Medical Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-03-15
Primary Completion
2024-06-15
Completion
2024-06-15

Countries

  • United States
  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06342427 on ClinicalTrials.gov